| Christoph Michael Prummer, MD | |
|
104 27th Ave Se, Puyallup, WA 98374-1145 | |
| (253) 770-9000 | |
| (253) 770-9712 |
| Full Name | Christoph Michael Prummer |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 9 Years |
| Location | 104 27th Ave Se, Puyallup, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740660638 | NPI | - | NPPES |
| 2158054 | Medicaid | WA | |
| 440476 | Other | WA | WA LABOR & INDUSTRIES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | MD61039326 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Multicare Good Samaritan Hospital | Puyallup, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Proliance Surgeons Inc Ps | 8527972900 | 388 |
News Archive
Researchers on Mayo Clinic's Florida campus have shut down one of the most common and lethal forms of lung cancer by combining the rheumatoid arthritis drug auranofin with an experimental targeted agent.
Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% is the first nasal antihistamine to offer convenient once-daily dosing for patients who suffer from seasonal allergies.
An investigation published in the current issue of Psychotherapy and Psychosomatics addresses the potential efficacy of a specialized psychotherapy in bulimia nervosa and binge eating disorder.
A new study of young people experiencing a first episode of psychosis reports elevations in the brain chemicals glutamate and glycine. Published in Biological Psychiatry, the study led by Dr. Dost öngür of Harvard Medical School provides the first-ever measurement of glycine levels in patients with psychotic disorders.
› Verified 7 days ago
| Entity Name | The Vancouver Clinic Inc Ps |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992759427 PECOS PAC ID: 3173436490 Enrollment ID: O20031111000793 |
News Archive
Researchers on Mayo Clinic's Florida campus have shut down one of the most common and lethal forms of lung cancer by combining the rheumatoid arthritis drug auranofin with an experimental targeted agent.
Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% is the first nasal antihistamine to offer convenient once-daily dosing for patients who suffer from seasonal allergies.
An investigation published in the current issue of Psychotherapy and Psychosomatics addresses the potential efficacy of a specialized psychotherapy in bulimia nervosa and binge eating disorder.
A new study of young people experiencing a first episode of psychosis reports elevations in the brain chemicals glutamate and glycine. Published in Biological Psychiatry, the study led by Dr. Dost öngür of Harvard Medical School provides the first-ever measurement of glycine levels in patients with psychotic disorders.
› Verified 7 days ago
| Entity Name | Proliance Surgeons Inc Ps |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023170313 PECOS PAC ID: 8527972900 Enrollment ID: O20031119000128 |
News Archive
Researchers on Mayo Clinic's Florida campus have shut down one of the most common and lethal forms of lung cancer by combining the rheumatoid arthritis drug auranofin with an experimental targeted agent.
Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% is the first nasal antihistamine to offer convenient once-daily dosing for patients who suffer from seasonal allergies.
An investigation published in the current issue of Psychotherapy and Psychosomatics addresses the potential efficacy of a specialized psychotherapy in bulimia nervosa and binge eating disorder.
A new study of young people experiencing a first episode of psychosis reports elevations in the brain chemicals glutamate and glycine. Published in Biological Psychiatry, the study led by Dr. Dost öngür of Harvard Medical School provides the first-ever measurement of glycine levels in patients with psychotic disorders.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christoph Michael Prummer, MD Po Box 1205, Puyallup, WA 98371-0231 Ph: (253) 770-9000 | Christoph Michael Prummer, MD 104 27th Ave Se, Puyallup, WA 98374-1145 Ph: (253) 770-9000 |
News Archive
Researchers on Mayo Clinic's Florida campus have shut down one of the most common and lethal forms of lung cancer by combining the rheumatoid arthritis drug auranofin with an experimental targeted agent.
Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% is the first nasal antihistamine to offer convenient once-daily dosing for patients who suffer from seasonal allergies.
An investigation published in the current issue of Psychotherapy and Psychosomatics addresses the potential efficacy of a specialized psychotherapy in bulimia nervosa and binge eating disorder.
A new study of young people experiencing a first episode of psychosis reports elevations in the brain chemicals glutamate and glycine. Published in Biological Psychiatry, the study led by Dr. Dost öngür of Harvard Medical School provides the first-ever measurement of glycine levels in patients with psychotic disorders.
› Verified 7 days ago
Dr. Todd Dwyer Jones, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 104 27th Ave Se, Puyallup, WA 98374 Phone: 253-770-9000 Fax: 253-770-9712 | |
Vivian Mae Yu, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 104 27th Ave Se, Puyallup, WA 98374 Phone: 253-770-9000 Fax: 253-770-9712 | |
Julie Allina Gustafson, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 104 27th Ave Se, Puyallup, WA 98374 Phone: 253-848-0368 Fax: 253-435-4937 | |
Randall Paul Bennett, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 104 27th Ave Se, Puyallup, WA 98374 Phone: 253-770-9000 Fax: 253-770-9712 | |
Douglas D Backous, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 104 27th Ave Se, Puyallup, WA 98374 Phone: 253-770-9000 Fax: 253-770-9712 | |
Dr. William Sterling Duke, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1609 S Meridian, Puyallup, WA 98371 Phone: 253-697-8980 | |
Dr. Greg E. Davis, MD, MPH Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 104 27th Ave Se, Puyallup, WA 98374 Phone: 253-770-9000 Fax: 253-770-9712 |